A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: A new paradigm

Antiviral Therapy

Volumn 6, Issue SUPPL. 3, 2001, Pages 45-54

  Lange, J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CROSS RESISTANCE; DRUG CHOICE; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034785517     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
4. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
5. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
6. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
7. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
8. 4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
10. Predictors of optimal virological response to potent antiretroviral therapy
11. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
12. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort
13. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy
14. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
15. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
16. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study
17. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
18. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen and its determinants
19. Aides federation nationale; November 1999 survey
20. Prospective prediction of ARV adherence: The role of patient-perceived barriers
21. Meta-analysis of efficacy of triple combination therapy in antiretroviral-naive HIV-1-infected adults
22. Risk factors for non-adherence in a human immunodeficiency virus (HIV) infected veterans population
23. Adherence to anti-HIV treatment in clinical practice
24. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy: Pharmacological data from the Viradapt study
25. Impact of individual pharmacokinetic parameters and drug resistance on virologic response to ritonavir-saquinavir-containing regimens
26. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir
27. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
28. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
29. Analysis of HIV phenotypic cross-resistance to protease inhibitors in patients failing on combination therapies
30. Virologic responses to a ritonavir - Saquinavir-containing regimen in patients who had previously failed nelfinavir
31. ABT-378/ritonavir (ABT-387/r) suppresses HIV RNA to <400 copies/mL in 95% of treatment-naïve patients and in 78% of PI-experienced patients at 36 weeks
32. Ritonavir (RTV)/Amprenavir (APV) combination therapy in HIV infected patients who failed several protease inhibitor containing regimen
33. Sequencing of non-nucleoside reverse transcriptase inhibitors based on specific mutational patterns fails to lower plasma HIV-RNA levels in persons extensively pre-treated with antiretrovirals who are failing virologically on nevirapine-containing antiretroviral regimens
34. Efavirenz (EFV) and adefovir (ADV)-based salvage in antiretroviral experienced HIV+ patients
35. Cross-resistance among NNRTIs: Evaluation of the option of recycling efavirenz after nevirapine failure
36. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
37. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
38. Resistance and viral response to stavudine/lamivudine combination in zidovudine, didanosine and zalcitabine experienced patients in the ALTIS 2 ANRS trial
39. Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history
40. Prior treatment with mono or dual NRTIs before HAART as predictor of virological failure in simplified abacavir-based triple NRTI regimens: Results from the Simplified Maintenance Trial (SMT) and CNA30017
41. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
42. Presence of thymidine analogs mutations and virologic response to non nucleoside reverse transcriptase inhibitors
43. Identification of a set of 'nucleoside associated mutations' (NAMS) that are the common cause of nucleoside cross-resistance
44. Mechanism of virological failure after substitution of a protease inhibitor by nevirapine in patients with controlled HIV-1 RNA
45. Drug resistance mutations in patients initiating protease inhibitor (PI)-containing HAART with either nelfinavir or indinavir in a population-based cohort
46. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
47. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine
48. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
49. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
50. Occurrence of thymidine-associated mutations in naive patients treated more than 6 months by stavudine/lamivudine bi-therapy combination and tri-therapies including stavudine/didanosine or stavudine/lamivudine
51. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
52. Mutations in the reverse transcriptase genome of HIV-1 isolates derived from subjects treated with didanosine and stavudine in combination
53. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy
54. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy
55. Differing RT mutation patterns in persons experiencing viral rebound on first-line regimens with d4T/ddI and d4T/3TC
56. Patterns of HIV drug resistance in routine clinical practice: A survey of almost 12000 samples from the USA in 1999
57. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial